

## Synthesis and biological studies of some novel formazans

B.C. REVANASIDDAPPA\* and E.V.S. SUBRAHMANYAM

Department of Pharmaceutical Chemistry, NGSM Institute of Pharmaceutical Sciences,  
Paneer, Deralakatte - 574 160 (India).

(Received: August 03, 2009; Accepted: September 18, 2009)

### ABSTRACT

A new series of formazans (3a-3l) were synthesized containing the INH moiety, INH upon reaction with substituted aromatic aldehydes yields the Schiff bases (2a-2c). Schiff bases on condensation with different diazonium salts will give formazans. The structure of the final newly compounds were assigned on the basis of IR, <sup>1</sup>H NMR and MASS spectral data. All the compounds of this series were evaluated for their *In-vitro* antibacterial and antifungal activity. Some of the compounds showed promising biological activity.

**Key words:** Formazans, azo compounds, Schiff bases, anti bacterial and anti fungal activity.

### INTRODUCTION

Schiff bases exhibit good antibacterial activity and pharmacological activity. These agents are one of the important synthons for the synthesis of a variety of heterocyclic compounds. Furthermore, formazans nucleus is known to be pharmacophoric in nature. A number of formazans derivatives possess antifertility<sup>1</sup>, antiviral<sup>1</sup>, anti-inflammatory<sup>2</sup>, antiparkinsonian<sup>3</sup>, CNS depressant<sup>4</sup>, anticancer, and anti-HIV activities. In the light of the above observations a new series of formazans were synthesized containing the INH moiety.

The title compounds were prepared by the reaction sequence as depicted in Scheme-01. INH upon reaction with substituted aromatic aldehydes in presence of few drops of glacial acetic acid will yields the intermediate schiff bases. Various diazonium salts were prepared by the reaction between amines in glacial acetic acid and HCl was

diazotized in the cold condition with sodium nitrite. The prepared diazonium salts were condensed with INH moiety in a mixture of DMF and pyridine to yield the title compounds. The structures of the above compounds were confirmed by IR, <sup>1</sup>H NMR and MASS spectral data. The compounds were screened for their in vitro antibacterial and antifungal activity.

### EXPERIMENTAL

Thin layer chromatography was used to monitor the reactions and purity of the newly synthesized compounds. The melting points were determined in open capillary tubes are uncorrected. IR spectra were recorded on a Shimadzu Perkin-Elmer 8201 FT-IR spectrophotometer. The <sup>1</sup>H NMR spectra were recorded on BRUKER AVANCE II 400 NMR SPECTROMETER in CDCl<sub>3</sub> and DMSO-d<sub>6</sub> using TMS as internal reference (chemical shifts in δ ppm). The FAB mass spectra were recorded on

JEOL SX-102/DA-6000 Mass spectrometer operating at 70ev.

#### Synthesis of Schiff bases

A mixture of hydrazide (0.01 mol) and substituted aromatic aldehydes (0.01 mol) in absolute alcohol (35 ml), in presence of catalytic amount of glacial acetic acid was refluxed for about 6-7 hrs. The reaction mixture was cooled and poured into the crushed ice. The precipitated compound was filtered and washed with water and recrystallised from absolute alcohol. The physical data of schiff bases (2a-2c) is given in Table-01.

2b IR (KBr) ( $\text{cm}^{-1}$ ): 3061 (CH-Ar), 1676 (C=O), 1593 (C=C).

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$  ppm: 3.09 (s,3H,  $\text{CH}_3$ ), 7.14-8.42 (m, 8H, Ar-H, Ar-CH),

11.77 (s, 1H, CONH) MS: m/z: 239[M $^+$ ].

2c: IR (KBr) ( $\text{cm}^{-1}$ ): 3037 (CH-Ar), 1664 (C=O), 1544(C=C).


$^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$  ppm: 7.32-8.75 (m, 8H, Ar-H, Ar-CH),

11.94(s, 1H, CONH) MS: m/z:259 [M $^+$ ].

#### Synthesis of formazans<sup>7</sup>

The appropriate amine (0.01 mol) in gl.acetic acid (2ml) and HCl (1.5 ml) was diazotized with sodium nitrite (0.2 g in 2ml of water) in the cold (0-5°C) medium. The resultant diazonium chloride solution was added with stirring to the schiff base (0.01 mol in DMF + Pyridine), and the resulting dark coloured solution was left overnight at room temperature and then poured onto crushed ice. The solid thus obtained, was recrystallised from ethanol/aqueous alcohol.

SCHEME-01



Scheme 1.

**3a: IR (KBr) (cm<sup>-1</sup>)** 2915 (CH-Ar), 1656(C=O), 1559(N=N), 1599 (C=C). **<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ ppm:** 7.26-8.80 (m, 12H, Ar-H), 10.10(s, 1H, CONH) MS:

m/z: 329 [M<sup>+</sup>].

**3g: <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ ppm:** 2.40 (s,3H, CH<sub>3</sub>), 7.20-8.77 (m, 12H, Ar-H), 9.61(s, 1H, CONH).

**3h: <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ ppm:** 2.39 (s,3H, CH<sub>3</sub>), 7.34-8.79 (m, 12H, Ar-H),

11.84(s, 1H, CONH). MS: m/z: 422 [M<sup>+</sup>].

**3j: IR (KBr) (cm<sup>-1</sup>):** 1667 (C=O), 1557(N=N), 1595 (C=C). **<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ ppm:** 7.30-8.81 (m, 12H, Ar-H), 9.94 (s, 1H, CONH).

**3l: IR (KBr) (cm<sup>-1</sup>):** 3110 (CH-Ar), 1680(C=O), 1570(N=N), 1590 (C=C). **<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ ppm:**

**Table 1: Physical data of Schiff bases (2a-2c)**

Comp	R-CHO	m.p. (°C)	% yield
2a	C <sub>6</sub> H <sub>5</sub>	108	66
2b	4-CH <sub>3</sub>	136	68
2c	4-Cl	173	70

**Table 2: Physical data of Formazans (3a-3l)**

Comp.	R-CHO	R <sub>1</sub> -NH <sub>2</sub>	MP (°C)	% Yield
3a	C <sub>6</sub> H <sub>5</sub>	C <sub>6</sub> H <sub>5</sub> NH <sub>2</sub>	S	61
3b	C <sub>6</sub> H <sub>5</sub>	4-CH <sub>3</sub>	156	64
3c	C <sub>6</sub> H <sub>5</sub>	4-Cl	134	66
3d	C <sub>6</sub> H <sub>5</sub>	Sulphadiazine	176	61
3e	4-CH <sub>3</sub>	C <sub>6</sub> H <sub>5</sub> NH <sub>2</sub>	144	71
3f	4-CH <sub>3</sub>	4-CH <sub>3</sub>	116	58
3g	4-CH <sub>3</sub>	4-Cl	166	63
3h	4-CH <sub>3</sub>	Sulphadiazine	186	69
3i	4-Cl	C <sub>6</sub> H <sub>5</sub> NH <sub>2</sub>	154	55
3j	4-Cl	4-CH <sub>3</sub>	107	62
3k	4-Cl	4-Cl	192	67
3l	4-Cl	Sulphadiazine	162	63

**Table 3: Antimicrobial and antifungal activities of compounds 3a-l**

Comp	Diameter of zone of inhibition (mm) at 10μg/ml concentration					
	<i>S.aureus</i>	<i>B.subtilis</i>	<i>E.coli</i>	<i>P.aeruginosa</i>	<i>C.albicans</i>	<i>A.niger</i>
3a	8	11	13	9	10	11
3b	14	13	8	14	11	12
3c	13	9	14	13	8	10
3d	12	11	9	11	11	9
3e	8	12	14	15	12	11
3f	12	12	9	8	13	10
3g	11	10	14	13	12	9
3h	10	10	9	16	10	12
3i	12	8	11	13	13	13
3j	9	11	7	14	12	12
3k	13	11	14	9	11	12
3l	12	11	8	14	10	11
Streptomycin	22	23	24	22	-	-
Griseofulvin	-	-	-	-	23	24
Control (DMF)	-	-	-	-	-	-

7.31-8.76 (m, 12H, Ar-H), 11.78(s, 1H, CONH).  
3k:  $^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\text{ppm}$ : 7.34-8.81 (m, 12H, Ar-H), 12.00(s, 1H, CONH).

Similarly other derivatives (3a-3l) were synthesized and their physical data is given in Table-02.

#### **Antibacterial And antifungal activity**

The newly synthesized formazans was assayed in vitro for antibacterial activity *S.aureus*, *P.aeruginosa*, *E.coli* and *B.subtilis* and antifungal activity against *C.albicans* and *A.niger* using DMF as solvent at 100  $\mu\text{g/ml}$  concentration by cup-plate method<sup>8</sup>. After 24 hr of incubation at  $37^\circ\text{C}$ , the zones of inhibition were measured in mm. The activity was compared with the known antibiotics viz. Streptomycin and Griseofulvin at the same concentration. The biological data of the compounds (3a-l) is given in table-03.

#### **RESULTS AND DISCUSSION**

The antibacterial activity of the newly synthesized compounds in the present investigation was assessed by the cup-plate method. The result of the antibacterial studies are shown in table-3. Among the compounds tested 4b, 4e, 4g, 4i showed good activity against both the gram positive and gram negative pathogenic organisms. The rest of the compounds showed moderate activity against all the four organisms.

In the antifungal activity, the compounds 4b and 4h showed highest activity against both the fungal organisms. The other compounds showed moderate activity.

#### **ACKNOWLEDGEMENTS**

The authors are thankful to NITTE Education Trust for providing the necessary facilities. The authors are also grateful to the Directors, RSIC, Chandigarh and CDRI, Lucknow for providing IR, NMR and Mass spectra respectively.

#### **REFERENCES**

1. Desai JM, and Shah VH, *Indian J. Chem.*, **42B**: 631 (2003).
2. Tandon M, Kumar P, Tandon P, Bhalla TN and Bhartwal JP, *Indian Drugs*, **21**: 24 (1983).
3. Srivastava VK, Palit G and Shanker K, *Indian Drugs*, **24**: 325 (1987).
4. Sathi G, Gujrati VR, Nath C, Agarwal JC, Bhargava KP and Shanker K, *Arzneimittel-Forsch* **33**: 1218 (1983).
5. Bhardwaj SD, Phatak P and Jooly VS, *Oriental J Chem.*, **2**: 181 (1995).
6. Venkal NK, *J. Med. Chem.*, **8**: 11 (1998).
7. Kalsi R, Pande K, Bhalla TN, Barthwal JP, Gupta GP, Parmar SS, *J. Pharm. Sci.*, **79**(4): 317 (1990).
8. R. Cruichshank, J. P. Duguid, B. P. Marmoin and H.A. Swan, *The Practice of Medical Microbiology*, **2**, **12<sup>th</sup> Edn.**, Churchill Livingstone, London 190 (1975).